Verubecestat

Verubecestat
Clinical data

ATC code	None
Legal status
Legal status	Investigational
Identifiers
Synonyms	MK-8931
CAS Number	1286770-55-5
PubChem (CID)	51352361
ChemSpider	31399364
UNII	J1I0P6WT7T
KEGG	D10739
Chemical and physical data
Formula	C₁₇H₁₇F₂N₅O₃S
Molar mass	409.41 g·mol⁻¹
3D model (Jmol)	Interactive image
SMILES C[C@]1(CS(=O)(=O)N(C(=N1)N)C)c2cc(ccc2F)NC(=O)c3ccc(cn3)F
InChI InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1 Key:YHYKUSGACIYRML-KRWDZBQOSA-N

Verubecestat (MK-8931) is an experimental drug for the treatment of Alzheimer's disease.^[1] It is an inhibitor of beta-secretase 1 (BACE1).^[2]^[3]

References

↑ Simon Makin (November 2, 2016). "New Alzheimer's Drug Clears Milestone in Human Clinical Trial". Scientific American.
↑ Forman, Mark; Kleijn, Huub-Jan; Dockendorf, Marissa; Palcza, John; Tseng, Jack; Canales, Christina; Egan, Michael; Kennedy, Matthew; Laterza, Omar; Ma, Lei; Scott, Jack; Tanen, Michael; Apter, Jeffrey; Backonja, Miroslav; Ereshefsky, Larry; Gevorkyan, Hakop; Jhee, Stanford; Rynders, Rebecca; Zari, Arian; Bryan, Ellie; Wagner, John; Troyer, Matthew; Stone, Julie (2013). "The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease". Alzheimer's & Dementia. 9 (4): P139. doi:10.1016/j.jalz.2013.04.083.
↑ Yan, Riqiang; Vassar, Robert (2014). "Targeting the β secretase BACE1 for Alzheimer's disease therapy". The Lancet Neurology. 13 (3): 319. doi:10.1016/S1474-4422(13)70276-X. PMID 24556009.

This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.